Rhythm Pharmaceuticals $RYTM became the latest biotech to tap into a buoyant market, raising $120 million in an IPO that went over the range at $17 a share. And they can add substantially to that if the underwriters pick up another million shares on the table.
{iframe}https://endpts.com/rhythm-pharma-goes-over-the-top-snags-120m-in-latest-sign-the-biotech-window-is-wide-open/{/iframe}